Cardiovascular gene therapy with vascular endothelial growth factors |
| |
Authors: | Seppo Ylä -Herttuala |
| |
Affiliation: | A.I. Virtanen Institute, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Gene Therapy Unit, Kuopio University Hospital, P.O. Box 1777, FI-70211 Kuopio, Finland; Research Unit, Kuopio University Hospital, P.O. Box 1777, FI-70211 Kuopio, Finland |
| |
Abstract: | Therapeutic angiogenesis with vascular endothelial growth factors (VEGFs) is a promising approach for the treatment of ischemic myocardium and peripheral skeletal muscles. Preclinical studies in large animals have clearly demonstrated safety and efficacy of VEGF gene therapy in clinically relevant disease models. However, first clinical trials with intravascular delivery of VEGF vector constructs have only resulted in limited benefits to the patients. Second generation VEGF-based gene therapy trials are based on direct intramyocardial and intraskeletal muscle injections in order to achieve better transfection efficiency and more targeted effects. Phase I/II studies are currently ongoing to test safety, feasibility and efficacy of these improved approaches in patients with severe cardiovascular diseases. |
| |
Keywords: | VEGF, vascular endothelial growth factor AAV, adeno-associated virus CRP, C-reactive protein lacZ, beta-galactocidase MRI, magnetic resonance imaging Adv, adenovirus SPECT, single-photon emission computed tomography PET, positron emission tomography 18F-FDG, 18F-fluorodeoxyglucose GMP, good manufacturing practice |
本文献已被 ScienceDirect 等数据库收录! |
|